SPOP and prostate carcinoma: Interestingly, the A646D mutation is reported to reduce AR:SPOP affinity and is frequently observed in patients with partial androgen insensitivity syndrome (PAIS), mild androgen insensitivity syndrome (MAIS), and prostate cancer [48,49] (COSMIC legacy identifier- COSM6906185 [50]).